McGill University has mandated St-Denis Thompson to carry out the following project: Montreal Neurological Institute / 22-035 - Priority building envelop repairs, balustrade.
The project consists of removing the stone balustrade.
Project manager: Johanne Guertin - Johanne.guertin [at] gph-inc.com
Assistant project manager: Gabriel Fortin - Gabriel.fortin [at] gph-inc.com
Construction start date: November 14, 2023
McGill University has mandated Ardec Construction Inc. to carry out the following project: Montreal Neurological Institute / 18-121 - Cyclotron aerial exhaust.
The project consists of installing the aerial conduit to replace the existing one at the Montreal Neurological Institute hospital.
Project manager: Eric Boutet, CIMA+ - eric.boutet [at] cima.ca ">eric.boutet [at] cima.ca
A study of more than 22,000 people with multiple sclerosis has discovered the first genetic variant associated with faster disease progression, which can rob patients of their mobility and independence over time.
Today the Canadian Institutes of Health Research (CIHR) announced funding for a new clinical trial consortium co-chaired by Dr. Guy Rouleau, Director of The Neuro (Montreal Neurological Hospital-Institute).
The Neuro’s director, Dr. Guy Rouleau, has been elected first vice-president of the World Federation of Neurology. The first vice-president and other WFN officers are elected by delegates from its 122 neurological societies around the world.
The mission of the WFN is to foster quality neurology and brain health worldwide by promoting global neurological education and training with emphasis placed firmly on under-resourced parts of the world.
$4.67M from Brain Canada will help probe the brain’s mysteries and create international research links
Research at The Neuro’s McConnell Brain Imaging Centre (BIC) of McGill University will receive a major boost thanks to a $4.67M grant from Brain Canada’s Platform Support Grant (PSG) program.
Program brings together multidisciplinary teams with expertise in various areas of neurodegenerative disease
Researchers at The Neuro (Montreal Neurological Institute-Hospital) make up a large part of eight projects funded by ALS Canada and the Brain Canada Foundation as part of their 2020 Discovery Grant Program, which brings together multidisciplinary research teams with expertise in various areas of ALS and neurodegenerative diseases to investigate critical areas of disease processes and clinical care.
Brain Canada program supports paradigm-shifting neuroscience that improves the lives of Canadians
Four researchers at The Neuro — Boris Bernhardt, Yasser Iturria-Medina, Jean-Francois Poulin, and Jo Anne Stratton — have received grants to support their work in the early-career stage, after being chosen from 150 talented applicants.
Brain Canada’s Future Leaders in Canadian Brain Research Program, anchored by a $5M gift from the Azrieli Foundation, enables paradigm-changing research of the brain to improve the lives of all Canadians.
Djavad Mowafaghian Foundation shares The Neuro’s open science vision to accelerate drug discovery and find new and effective treatments for autism spectrum disorders
Sylvain Baillet, chercheur à l'Institut neurologique de Montréal, étudie la mémoire de travail auditive, cette mémoire qui nous permet de retenir les derniers sons entendus pendant quelques secondes - une faculté importante qui nous permet entre autres de suivre une conversation. Il a noté que la stimulation magnétique a amélioré cette forme de mémoire chez ses sujets.
A new research centre in Montreal will help lift the shroud of mystery surrounding autism spectrum disorder (ASD), and lead to the development of better diagnostic tools and more effective therapies for people with autism.
The ability to remember sounds, and manipulate them in our minds, is incredibly important to our daily lives — without it we would not be able to understand a sentence, or do simple arithmetic. New research is shedding light on how sound memory works in the brain, and is even demonstrating a means to improve it.
KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co- developing since 2015.
The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom- engineered therapeutic developed at NRC.
McGill Newsroom
Chemicals found to improve low-light vision of tadpoles by sensitizing retinal cells
A multidisciplinary team including researchers from the Montreal Neurological Institute has improved our understanding of how cannabinoids, the active agent in marijuana, affect vision in vertebrates.
